title: Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice.
abstract: Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disease that destroys memory and cognitive function. Aggregates of hyperphosphorylated tau protein are a prominent feature in the brain of patients with AD, and are a major contributor to neuronal toxicity and disease progression. However, the factors that initiate the toxic cascade that results in tau hyperphosphorylation in sporadic AD are unknown. Here we investigated whether degeneration of basal forebrain cholinergic neurons (BFCNs) and/or a resultant decrease in neurotrophin signaling cause aberrant tau hyperphosphorylation. Our results reveal that the loss of BFCNs in pre-symptomatic pR5 (P301L) tau transgenic mice results in a decrease in hippocampal brain-derived neurotrophic factor levels and reduced TrkB receptor activation. However, there was no exacerbation of the levels of phosphorylated tau or its aggregation in the hippocampus of susceptible mice. Furthermore the animals' performance in a hippocampal-dependent learning and memory task was unaltered, and no changes in hippocampal synaptic markers were observed. This suggests that tau pathology is likely to be regulated independently of BFCN degeneration and the corresponding decrease in hippocampal neurotrophin levels, although these features may still contribute to disease etiology.
authors: Marion T
authors: MT
authors: Turnbull
authors: Elizabeth J
authors: EJ
authors: Coulson
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D066187:Basal Forebrain / Q000473:pathology*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D059329:Cholinergic Neurons / Q000187:drug effects / Q000473:pathology; D002802:Cholinesterases / Q000378:metabolism; D005260:Female; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D000922:Immunotoxins / Q000633:toxicity; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics; D019636:Neurodegenerative Diseases / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D010320:Parvalbumins / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D020813:Receptor, trkB / Q000378:metabolism; D054789:Ribosome Inactivating Proteins, Type 1 / Q000633:toxicity; D000076985:Saporins; D012686:Septal Nuclei / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D016875:tau Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D000922:Immunotoxins; D010320:Parvalbumins; D054789:Ribosome Inactivating Proteins, Type 1; D016875:tau Proteins; D020813:Receptor, trkB; D000110:Acetylcholinesterase; D002802:Cholinesterases; D000076985:Saporins
keywords: Alzheimer’s disease; basal forebrain; brain-derived neurotrophic factor (BDNF); cholinergic neuron; hippocampus; lesion; neurotrophin; tau hyperphosphorylation